Interferon-tau inhibits the development of diabetes in NOD mice

Autoimmunity

Volumn 41, Issue 7, 2008, Pages 543-553

  Sobel, Douglas O ^a   Ahvazi, Behrouz ^a   Amjad, Fahd ^a   Mitnaul, Larry ^a   Pontzer, Carol ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Bldg 142   (United States)

Author keywords

Diabetes mellitus; Interferon tau; NOD; Type 1 interferon

Indexed keywords

ALPHA INTERFERON; CONCANAVALIN A; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; TAU INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EFFECTOR CELL; FEMALE; IMMUNOREGULATION; INSULITIS; LOW DRUG DOSE; LYMPHOCYTE COUNT; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET CELL; PANCREATITIS; SPLEEN CELL;

ADOPTIVE TRANSFER; ANIMALS; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I; INTERFERON-GAMMA; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; PREGNANCY PROTEINS; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 54549083551     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802194195     Document Type: Article

References (48)

1. Makino, S. and Tochino, Y. (1978) The spontaneously nonobese diabetic mouse. Exp Anim, 27, pp. 27-29.
2. Martignal, L., Elmansour, A., Audrain, M., Julian, JF, Charbonnel, B. and Sai, P. (1995) Pancreatic expression of antigen for islet cell antibodies in nonobese diabetic mice. J Autoimmun, 8, pp. 465-482.
3. Kolika, T., Itoh, Y., Ishiti, T., Ito, I., Takabayashi, K., Maruyama, N., Tomioka, H. and Yoshida, S. (1987) Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes, 36, pp. 539-541.
4. Barnard, NF, Ertug, F. and Margolese, H. (1992) High incidence of thyroiditis and anti-thyroid antibodies in NOD mice. Diabetes, 41, pp. 40-46.
5. Adam, C., Thoua, TY, Ronco, P., Varroust, P., Tovey, M. and Moral-Maroger, L. (1980) The effect of exogenous interferon: Acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol, 40, pp. 373-382.
6. Stewart, TA, Hultgren, B., Huang, X., Pitts-Meek, S., Hully, J. and MacLachlan, NJ (1993) Induction of type 1 diabetes by interferon-α in transgenic mice. Science, 260, pp. 1942-1946.
7. Sobel, DO and Ahvazi, B. (1998) α-Interferon inhibits the development of diabetes in NOD mice. Diabetes, 47, pp. 1867-1872.
8. Sobel, DO, Creswell, K., Yoon, JW and Holterman, D. (1998) Alpha interferon administration paradoxically inhibits the development of diabetes in BB rats. Life Sci, 62, pp. 1293-1302.
9. Pontzer, CH, Bazer, FW and Johnson, HM (1991) Antiproliferative activity of a pregnancy hormone, ovine trophoblast protein-1. Cancer Res, 51, pp. 5304-5307.
10. Bazer, FW, Spencer, TE and Ott, L. (1996) Placental interferons. Am J Reprod Immunol, 35, pp. 297-308.
11. Li, J. and Roberts, RM (1994) Interferon-tau and interferon-τ interact with the same receptors in bovine endometrium: Use of a readily iodinatable form of recombinant interferon-tau for binding studies. J Biol Chem, 269, p. 13544.
12. Subramanian, PS, Khan, SA, Pontzer, CH and Johnson, HM (1995) Differential recognition of the type I receptor by IFN-τ and IFN-alpha is responsible for their differential cytotoxicity. Proc Natl Acad Sci USA, 92, pp. 12270-12274.
13. Radhakrishnan, R., Walter, LJ, Subramaniam, PS, Johnson, HM and Walter, MR (1999) Crystal structure of ovine interferon-tau at 2.1 A resolution. J Mol Biol, 286, pp. 151-162.
14. Pontzer, CH, Ott, TL, Bazer, FW and Johnson, HM (1994) Structure/ function studies with interferon tau: Evidence for multiple active sites. J Interferon Res, 14, p. 133.
15. Stewart, DM, Johnson, GA, Vyhlidal, CA, Burghardt, RC, Safe, SH, Yu-Lee, L-Y, Bazer, FW and Spencer, TE (2001) Interferon-tau activates multiple signal transducer and activator of transcription proteins and has complex effects on interferon-responsive gene transcription in ovine endometrial epithelial cells. Endocrinol, 142, p. 98.
16. Soos, JM, Subramanian, PS, Hobeika, AC, Schiffenbauer, J. and Johnson, HM (1995) The IFN pregnancy recognition hormone IFN-τ blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J Immunol, 155, p. 2747.
17. Soos, JM, Schiffenbauer, J., Johnson, HM and Pontzer, CH (1996) Interferon tau: A potential treatment for inflammatory central nervous system diseases. Interferon therapy of multiple sclerosis, pp. 479-498. Marcel Dekker, NY
18. Van Heeke, G., Ott, TL, Strauss, A., Ammaturo, D. and Bazer, FW (1996) High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris. J Interferon Cytokine Res, 16:2, pp. 119-126.
19. Pontzer, CH and Johnson, HM (1995) Measurement of interferons. Methods Neurosci, 24, pp. 3-9.
20. + regulatory T cells. J Immunol, 177, pp. 6603-6612.
21. + regulatory T cell migration requires - selectin expression: - selectin transcriptional regulation balances constitutive receptor turnover. J Immunol, 178, pp. 291-300.
22. + regulatory T cells restore normoglycemia in diabetic NOD mice. JEM, 204, pp. 191-201.
23. Yasunami, R. and Bach, JF (1988) Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol, 18, pp. 481-484.
24. Mujtaba, MG, Soos, JM and Johnson, HM (1997) CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J Neuroimmunol, 75, pp. 35-42.
25. Aune, TM and Pierce, CW (1982) Activation of suppressor T-cell pathway by interferon. Proc Natl Acad Sci USA, 79, pp. 3606-3812.
26. Serreze, DV and Lattar, EH (1988) Defective activation of T suppressor cell function in nonobese diabetic mice potential relation to cytokine deficiencies. J Immunol, 140, pp. 3801-3807.
27. + T-cells from patients with type 1 diabetes. Diabetes, 54, pp. 92-99.
28. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med, 188, pp. 287-296.
29. + regulatory T lymphocytes in neonatal NOD mice. Ann N Y Acad Sci, 105, pp. 72-87.
30. Bennett, CL, Christi, J., Ramsdell, F., Brunkow, ME, Ferguson, PJ, Whitesell, L., Kelly, TE, Saulsbury, FT, Chance, PF and Ochs, HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27, pp. 20-21.
31. + T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes, 55, pp. 2098-2105.
32. + regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes, 57, pp. 113-123.
33. + regulatory T cells for immunologic self-tolerance and negative control of immune response. Annu Rev Immunol, 22, pp. 531-562.
34. Banchereau, J. and Steinman, RM (1998) Dendritic cells and the control of immunity. Nature, 392, pp. 245-252.
35. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C. and Amigorena, S. (2002) Antigen Presentation and T cell stimulation by dendritic cells. Annu Rev Immunol, 20, pp. 621-667.
36. Dhodapkar, MV, Steinman, RM, Krasovsky, J., Munz, C. and Bhardwaj, C. (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med, 193, pp. 233-238.
37. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med, 192, pp. 1213-1222.
38. +T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med, 199, pp. 1467-1477.
39. + T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes, 55, pp. 2098-2105.
40. + cells in the pathogenesis of organ-specific autoimmune disease. Immunol Today, 16, pp. 34-38.
41. Nichilson, LB and Kuchroo, VK (1996) Manipulation of the TH1/TH2 balance in autoimmune disease. Curr Opin Immunol, 6, pp. 837-842.
42. Rogez-Kreuz, C., Maneglier, B., Dereuddre-Bosquet, N., Dormont, D. and Clayette, P. (2005) Lack of IFN-γ production in response to antigenic stimulation in human IFN-τ-treated lymphocytes. J Interferon Cytokine Res, 25, pp. 444-452.
43. + T cells. J Immunol, 175, pp. 7093-7097.
44. + T-cell clones in vivo. Diabetes, 45, pp. 1121-1131.
45. null mice are diabetes and insulitis resistant. Diabetes, 43, pp. 505-509.
46. Taki, T., Nagata, M., Ogawa, W., Hatamori, N., Hayakawa, M., Hari, J., Shii, K., Baba, S. and Yokono, K. (1991) Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. Diabetes, 40, pp. 1203-1209.
47. Brod, SA, Malone, M., Darcan, S., Papolla, M. and Nelson, L. (1998) Ingested interferon alpha suppresses type 1 diabetes in non-obese diabetic mice. Diabetologia, 41, pp. 1227-1232.
48. Soos, JM, Stüve, O., Youssef, S., Bravo, M., Johnson, HM, Weiner, HL and Zamvil, SS (2002) Cutting edge: Oral type I IFN-τ promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol, 169, pp. 2231-2235.